Abstract: The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.

Abstract: An ospemifene solid dispersion for enhancing solubility and bioavailability, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxyl propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation in the form of powder comprising at least a first and a second powder, in which at least said first powder contains an active agent in an amount greater than 1% by weight with respect to the weight of said first powder. Both the powders comprise leucine in an amount ranging from 5 to 70% by weight with respect to the weight of each powder and a sugar in an amount ranging from 20 to 90% by weight with respect to the weight of each powder. The composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 80.

Abstract: The present invention relates to a composition comprising particles of at least one polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4, at least one hydrocarbon-based oil and at least one amorphous hydrocarbon-based block copolymer obtained by polymerization of at least one monomer of unsaturated hydrocarbon type comprising 2 to 5 carbon atoms and containing one or two ethylenic unsaturations. The invention also relates to a process for making up and/or caring for keratin materials, in which said composition is applied.

Abstract: Nanoreactors comprising a metal precursor in a carrier are provided as well as methods of initiating, methods of preparing, and methods of using nanoreactors. In some embodiments, upon exposure to heat, the metal precursor forms nanoparticles that can be detected, e.g., by detecting a color change in the nanoreactor and/or by detecting the number and/or size and/or size distribution and/or shape of the nanoparticles. The nanoreactors can be used, in some embodiments, as time-temperature indicators for perishable goods.

Abstract: A self-healing polymer is described herein, including a first carbon nanotube filled with at least a first healing agent, wherein the first carbon nanotube has first and second ends, wherein a first end cap is closed on the first end of the first carbon nanotube and a second end cap is closed on the second end of the first carbon nanotube, and a second carbon nanotube filled with at least a second healing agent, wherein the second carbon nanotube has first and second ends, wherein a first end cap is closed on the first end of the second carbon nanotube and a second end cap is closed on the second end of the second carbon nanotube.

Abstract: A coating is described herein, including a material chosen from the group consisting of rubber, ceramic, metal, concrete, epoxy, polyurethane, and polyurea, a first carbon nanotube (FCN) filled with a first healing agent, wherein the first carbon nanotube has first and second ends, wherein a first FCN end cap is closed on the first end of the FCN and a second FCN end cap is closed on the second end of the FCN, and a second carbon nanotube (SCN) filled with a second healing agent, wherein the second carbon nanotube has first and second ends, wherein a first SCN end cap is closed on the first end of the SCN and a second SCN end cap is closed on the second end of the SCN, wherein the first and second carbon nanotubes are mixed in the material, wherein the end caps are removable by a hydrolysis reaction.

Abstract: The described invention provides compositions and methods for treating asthma, a disease, condition or pathologic process whose progression is characterized by one or more of aberrant fibroblast proliferation and extracellular matrix deposition producing constriction in an airway, airway remodeling, and airway obstruction in lung tissue. The method includes administering a pharmaceutical composition comprising a therapeutic amount of a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce the constriction of small airway dimensions and airway obstruction, treat airway remodeling, or a combination thereof.

Abstract: The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).

Abstract: Disclosed are a method for preparing hydroxypropyl methylcellulose acetate succinate (HPMCAS) grains and HPMCAS grains. The disclosed method for preparing HPMCAS grains comprises: a step of esterifying hydroxypropyl methylcellulose (HPMC), acetic anhydride, and succinic anhydride in a reaction medium in the presence of a catalyst so as to obtain a reaction solution containing HPMCAS (esterification step); and a step of continuously or intermittently putting the reaction solution into water so as to form grains (granulating step).

Abstract: Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.

Abstract: Brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery (CED) have been developed. In the preferred embodiment, these are loaded with FDA-approved compounds, identified through library screening to target brain cancer stem cells (BSCSs). The particles are formed by emulsifying a polymer-drug solution, then removing solvent and centrifuging at a first force to remove the larger particles, then collecting the smaller particles using a second higher force to sediment the smaller particles having a diameter of less than 100 nm, more preferably less than 90 nanometers average diameter, able to penetrate brain interstitial spaces.

Abstract: The present invention relates to light-converting materials which comprise semiconductor nanoparticles and an unactivated crystalline material, where the semiconductor nanoparticles are located on the surface of the unactivated crystalline material. The present invention furthermore relates to the use of the light-converting material in a light source. The present invention furthermore relates to a light-converting mixture, to a light source, to a lighting unit which contains the light-converting material according to the invention, and to a process for the production of the light source.

Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

Abstract: Provided herein are compositions and related methods for the treatment of herpes simplex virus (HSV) induced blisters and resulting ulcerative lesions. The composition includes at least one antiviral agent that is a long-chain aliphatic compound, and at least one topical corticosteroid.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation use in powder form comprising a first powder comprising at least a powder (a1) comprising an active agent or a pharmaceutically acceptable salt thereof, in an amount greater than 1% by weight of the powder, leucine in an amount from 5 to 70% by weight of said powder, a sugar in an amount from 20 to 90% by weight of the powder; and a second powder comprising a mixture of a first lactose which has an X50 from 35 to 75 ?m, with a second lactose which has an X50 from 1.5 to 10 ?m, the content of the first and second lactose in the mixture are respectively from 85% to 96% and from 4% to 15%.

Abstract: Lyophilized chromophoric polymer dot compositions are provided. Also disclosed are methods of making and using the lyophilized compositions, methods of dispersing the lyophilized compositions in aqueous solutions and kits supplying the compositions.

Abstract: This invention provides compositions and methods for preventing inflammatory diseases of the joints, including rheumatoid and osteoarthritis, tendonitis, bursitis, inflammation of the ligament, synovitis, gout, and systemic lupus erythematosus, wherein the methods include injecting into the inflamed joint a therapeutic anti-inflammatory composition comprising a bacterial or viral IL-10 expression construct, wherein the IL-10 expression construct comprises a bacterial or viral backbone and a nucleic acid sequence encoding interleukin-10.

Abstract: A cell for treating neurodegenerative disease treated with angelica extract is provided. The pharmaceutical composition comprises the cell for treating neurodegenerative disease and can significantly increase and recover the number of dopaminergic neurons to achieve the goal for treating neurodegenerative disease.

Abstract: There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution.

Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.

Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.

Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.

Abstract: The invention provides a metallopolymer coordination network comprising one or more coinage or similar metals and a glyme or glyme-equivalent. The composition has an amorphous polymer network that is significantly stronger than previously reported supramolecular hydrogels synthesized without glyme. Glyme chain length and water content strongly influence the mechanical, electronic, and optical behavior of the network.

Abstract: The invention relates to an antiviral pharmaceutical composition for topical use against those viruses with a lipid envelope, comprising, as active ingredients a cationic copolymer containing tertiary amine groups and a cationic surfactant containing quaternary ammonium groups.

Abstract: The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Abstract: The present invention relates to compositions containing (fat-soluble) active ingredients and/or colorants in a matrix based on modified plant gums, i.e. plant gums that have been submitted to hydrolysis to degrade either the protein portion and/or where appropriate, the polysaccharide, and to a process for preparing these compositions as well as to modified plant gums, whose protein part is hydrolyzed up to a degree of about 30%, preferably to a degree of from about 0.05 to about 30%, and/or whose polysaccharide part is hydrolyzed up to a degree of about 50%, a process for the manufacture thereof and such modified plant gums themselves. The present invention further relates to the use of the compositions of this invention for the enrichment, fortification and/or for the coloration of food, beverages, animal feed, cosmetics and pharmaceutical compositions and to such food, beverages, animal feed, cosmetics and pharmaceutical compositions themselves.

Abstract: A dry composition, comprising three-dimensional porous microparticles, wherein the microparticles comprise: (i) an active substance (eg a poorly water soluble drug), (ii) polymeric nanoparticles such as those composed of a biocompatible and/or biodegradable polymer (eg a PLGA polymer) (iii) lipid droplets (eg droplets of a medium chain triglyceride (MCT)), (iv) a nanoparticle stabilizing agent such as PVA or DMAB, and optionally, (v) a cryoprotectant (eg mannitol); wherein said active substance is carried by said nanoparticles and/or lipid droplets. The composition of the present invention may be formulated into, for example, a medicament for the treatment and/or prevention of various diseases or disorders (eg human or veterinary therapeutics). The average diameter of the individual microparticles of the composition, may be in the order of 2.5-3.5 ?m which are particularly suitable for administration to the lung.

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Abstract: The present invention relates to extravascular supports. In particular, to extravascular supports which are used in vein grafting. More in particular, it relates to extravascular supports which are biodegradable.

Abstract: The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration, suitable for the treatment of obstructive diseases of the airways, such as asthma and chronic obstructive pulmonary disease (COPD).

Abstract: Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

Abstract: A pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers, the solid matrix including a pharmaceutically active substance or a pharmaceutically acceptable salt thereof distributed homogeneously or substantially homogeneously within the matrix; wherein the pharmaceutically active substance is, for example, a gonadotropin releasing hormone (GnRH), a GnRH agonist or a GnRH antagonist.

Abstract: A method of controlling the inflammatory and/or neuropatic pain of various origins by administering a pharmaceutical composition containing palmitoylethanolamide, to a human or animal patient. In particular, the present invention relates to the administration of a pharmaceutical composition comprising palmitoylethanolamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, or L-acetylcysteine to a patient.

Abstract: The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.

Abstract: The present invention generally relates to microparticles and, in particular, to systems and methods for encapsulation within microparticles. In one aspect, the present invention is generally directed to microparticles containing entities therein, where the entities contain an agent that can be released from the microparticles, e.g., via diffusion. In some cases, the agent may be released from the microparticles without disruption of the microparticles. The entities may be, for instance, polymeric particles, hydrogel particles, droplets of fluid, etc. The entities may be contained within a fluid that is, in turn, encapsulated within the microparticle. The agent may be released from the entity into the fluid, and then from the fluid through the microparticle. In such fashion, the release of agent from the microparticle may be controlled, e.g., over relatively long time scales.

Abstract: The present disclosure relates to a taste-masking microcapsule composition. The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API.

Abstract: Disclosed are sublingual formulations of apomorphine, and methods of treating Parkinson's disease therewith. The sublingual formulations are films or strips having a first portion comprising apomorphine particles comprising an acid addition salt of apomorphine and a second portion comprising a pH neutralizing agent.

Abstract: Nanoparticles include a core, a hydrophilic layer around the core, and one or more mitochondrial targeting moieties, and may optionally include one or more contrast agents or one or more therapeutic agents. For effective mitochondrial targeting the nanoparticles have a diameter of about 200 nm or less or have a zeta potential of about 0 mV or more.

Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

Abstract: Method for producing sodium bicarbonate particles by spray-drying of an aqueous solution comprising 1 to 10% by weight of sodium bicarbonate and an additive selected from the group consisting of: magnesium salt, sodium alkylbenzene sulfonate and soybean lecithin. Sodium bicarbonate particles obtainable by such process and comprising at least 20 mg of the additive per kg of sodium bicarbonate particles.

Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene of 1 to 20 carbons or a linear alkenylene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Abstract: The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.

Abstract: The present invention is directed to transfection complexes of rosette nanotubes and one or more nucleic acids.

Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.